Morphine in Postoperative Patients: Pharmacokinetics and Pharmacodynamics of Metabolites

BACKGROUND: There is great variability in the need for morphine in the postoperative period. We performed a pharmacokinetic–pharmacodynamic study considering the potential effect of the two main metabolites of morphine. METHODS: Fifty patients with moderate to severe pain received morphine as an IV titration, followed by IM administration postoperatively. The plasma concentration of morphine, morphine-6-glucuronide (M-6-G), morphine-3-glucuronide (M-3-G), and pain intensity were measured at frequent intervals. Pharmacokinetic and pharmacodynamic fitting was performed with the software NONMEM. RESULTS: The pharmacokinetics were largely predictable. M-6-G and M-3-G clearances were markedly decreased in patients with renal failure. The pharmacodynamics was less predictable, with an important interindividual variability. M-6-G was 7.8 times more potent than morphine, but the average time to peak concentration in the effect compartment after a bolus injection of morphine was 4.25 h for M-6-G, when compared to 0.33 h for morphine. M-3-G showed mild inhibition of the analgesic properties of morphine and of M-6-G. The time to M-3-G peak concentration in the effect compartment after a bolus injection of morphine was 10 h. CONCLUSIONS: M-6-G is a potent opioid agonist and M-3-G a mild opioid antagonist. Both are poorly excreted in patients with renal failure. However, the metabolism of morphine was rapid when compared to the transfer of metabolites through the blood–brain barrier, which appears to be the limiting process. Because poor analgesia due to M-3-G’s effect may occur in some patients after 1 or 2 days, a switch to other molecules should be considered.

[1]  R. Moore,et al.  Systematic review of factors affecting the ratios of morphine and its major metabolites , 1998, Pain.

[2]  P. Coriat,et al.  Relationships between Measurement of Pain Using Visual Analog Score and Morphine Requirements during Postoperative Intravenous Morphine Titration , 2003, Anesthesiology.

[3]  K. Novak,et al.  From mouse to man , 2003, Nature Reviews Cancer.

[4]  T. Lieutaud,et al.  Preemptive Intravenous Morphine-6-glucuronide Is Ineffective for Postoperative Pain Relief , 2000, Anesthesiology.

[5]  J. Hasselstrøm,et al.  Morphine Pharmacokinetics and Metabolism in Humans Enterohepatic Cycling and Relative Contribution of Metabolites to Active Opioid Concentrations , 2022 .

[6]  L. Christrup,et al.  Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. , 2003, Journal of pain and symptom management.

[7]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[8]  S. Kaasa,et al.  Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy , 2002, European Journal of Clinical Pharmacology.

[9]  T. Jensen,et al.  Measurements of human pressure-pain thresholds on fingers and toes , 1989, Pain.

[10]  A. Paci,et al.  Evaluation of the pharmacokinetic profile and analgesic efficacy of oral morphine after total hip arthroplasty , 2006, European journal of anaesthesiology.

[11]  S. Joel,et al.  Limited phase I study of morphine-3-glucuronide. , 2001, Journal of pharmaceutical sciences.

[12]  J. Lötsch.  Opioid metabolites. , 2005, Journal of pain and symptom management.

[13]  J. Lötsch,et al.  Is morphine-3-glucuronide of therapeutic relevance? , 2005, Pain.

[14]  S. Joel,et al.  Randomized placebo‐controlled trial of the activity of the morphine glucuronides , 2000 .

[15]  J. Mogil,et al.  Sex differences in opioid analgesia , 1999 .

[16]  M. Fung,et al.  Randomized, Double-blind Study of the Analgesic Efficacy of Morphine-6-Glucuronide versus Morphine Sulfate for Postoperative Pain in Major Surgery , 2005, Anesthesiology.

[17]  A. Roche,et al.  Extrahepatic metabolism of morphine occurs in humans. , 1988, Clinical pharmacology and therapeutics.

[18]  K. Samii,et al.  Can immediate opioid requirements in the post-anaesthesia care unit be used to determine analgesic requirements on the ward? , 1995, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[19]  Jörn Lötsch,et al.  Pharmacokinetic modeling to predict morphine and morphine‐6‐glucuronide plasma concentrations in healthy young volunteers , 2002, Clinical pharmacology and therapeutics.

[20]  R. Craft.  Sex Differences in Opioid Analgesia: “From Mouse to Man” , 2003, The Clinical journal of pain.

[21]  A. Dahan,et al.  Sex Differences in Morphine Analgesia: An Experimental Study in Healthy Volunteers , 2000, Anesthesiology.

[22]  J. Mogil,et al.  The genetic mediation of individual differences in sensitivity to pain and its inhibition. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Coriat,et al.  Sex- and Age-related Differences in Morphine Requirements for Postoperative Pain Relief , 2005, Anesthesiology.

[24]  J. Lötsch,et al.  Are mu-opioid receptor polymorphisms important for clinical opioid therapy? , 2005, Trends in molecular medicine.

[25]  A. Somogyi,et al.  High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. , 1991, Journal of chromatography.

[26]  P. Macintyre,et al.  Age is the best predictor of postoperative morphine requirements , 1996, Pain.

[27]  U. Hofmann,et al.  Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. , 2002, British journal of clinical pharmacology.

[28]  L. Gagliese,et al.  The measurement of postoperative pain: A comparison of intensity scales in younger and older surgical patients , 2005, Pain.

[29]  A. Dahan,et al.  Polymorphism of &mgr;-Opioid Receptor Gene (OPRM1:c.118A>G) Does Not Protect Against Opioid-induced Respiratory Depression despite Reduced Analgesic Response , 2005, Anesthesiology.

[30]  J. Bradbury.  Why do men and women feel and react to pain differently? , 2003, The Lancet.

[31]  M. Slevin,et al.  Morphine intoxication in renal failure; the role of morphine-6-glucuronide. , 1986, British medical journal.

[32]  Gérard Saillant,et al.  Postoperative Morphine Consumption in the Elderly Patient , 2003, Anesthesiology.

[33]  Yannick Duguay,et al.  A novel functional polymorphism in the uridine diphosphate–glucuronosyltransferase 2B7 promoter with significant impact on promoter activity , 2004, Clinical pharmacology and therapeutics.

[34]  G. Dhonneur,et al.  Plasma and Cerebrospinal Fluid Concentrations of Morphine and Morphine Glucuronides after Oral Morphine: The Influence of Renal Failure , 1994, Anesthesiology.

[35]  F. Ruddle,et al.  Report of the committee on the genetic constitution of autosomes other than chromosomes 1,2 and 6. , 1976, Birth defects original article series.

[36]  A. Dahan,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Morphine-6-glucuronide-induced Analgesia in Healthy Volunteers: Absence of Sex Differences , 2004, Anesthesiology.

[37]  G. Hanks,et al.  Contribution to variability in response to opioids , 2005, Supportive Care in Cancer.

[38]  H. Thaler,et al.  The metabolite morphine‐6‐glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function , 1992, Clinical pharmacology and therapeutics.

[39]  M. Slevin,et al.  An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites. , 1988, Journal of chromatography.